Prevalence and evolution of transmitted human immunodeficiency virus drug resistance in Belgium between 2013 and 2019

Virginie Mortier, Laurent Debaisieux, Geraldine Dessilly, Karolien Stoffels, Dolores Vaira, Ellen Vancutsem, Kristel Van Laethem, Fien Vanroye, Chris Verhofstede

Research output: Contribution to journalA1: Web of Science-articlepeer-review

3 Downloads (Pure)

Abstract

Background To assess the prevalence and evolution of transmitted drug resistance (TDR) in Belgium, a total of 3708 baseline human immunodeficiency virus (HIV)-1 polymerase sequences from patients diagnosed between 2013 and 2019 were analyzed. Methods Protease and reverse-transcriptase HIV-1 sequences were collected from the 7 national Aids Reference Laboratories. Subtype determination and drug resistance scoring were performed using the Stanford HIV Drug Resistance Database. Trends over time were assessed using linear regression, and the maximum likelihood approach was used for phylogenetic analysis. Results A total of 17.9% of the patients showed evidence of TDR resulting in at least low-level resistance to 1 drug (Stanford score >= 15). If only the high-level mutations (Stanford score >= 60) were considered, TDR prevalence dropped to 6.3%. The majority of observed resistance mutations impacted the sensitivity for nonnucleoside reverse-transcriptase inhibitors (NNRTIs) (11.4%), followed by nucleoside reverse-transcriptase inhibitors (6.2%) and protease inhibitors (2.4%). Multiclass resistance was observed in 2.4%. Clustered onward transmission was evidenced for 257 of 635 patients (40.5%), spread over 25 phylogenetic clusters. Conclusions The TDR prevalence remained stable between 2013 and 2019 and is comparable to the prevalence in other Western European countries. The high frequency of NNRTI mutations requires special attention and follow-up. Phylogenetic analysis provided evidence for local clustered onward transmission of some frequently detected mutations.

Original languageEnglish
Article number195
JournalOpen Forum Infectious Diseases
Volume9
Issue number7
Pages (from-to)ofac195
Number of pages8
ISSN2328-8957
DOIs
Publication statusPublished - 2022

Keywords

  • HIV resistance
  • HIV transmission
  • prevalence
  • TDR
  • HIV-1 REVERSE-TRANSCRIPTASE
  • TREATMENT-NAIVE PATIENTS
  • PHENOTYPIC SUSCEPTIBILITY
  • ANTIRETROVIRAL THERAPY
  • MUTATIONS
  • TRANSMISSION
  • IMPACT
  • RILPIVIRINE
  • PROTEASE
  • INDIVIDUALS

Fingerprint

Dive into the research topics of 'Prevalence and evolution of transmitted human immunodeficiency virus drug resistance in Belgium between 2013 and 2019'. Together they form a unique fingerprint.

Cite this